Scholar Rock Holding SRRK 深 滬
等待開盤 08-15 09:30:00 美东时间
32.29
+0.310
+0.97%
華盛通- 最 高32.625
- 今 開31.76
- 成交量 96.38万股
- 最 低 31.695
- 昨 收 31.98
- 總市值 30.66亿
- 52周最高 46.98
- 市盈率 靜 --
- 換手率 1.02%
- 52周最低 6.76
- 委 比 -45.05%
- 總股本 9494.56万
- 歷史最高 70.00
- 量 比 0.54
- 振 幅 2.91%
- 歷史最低 4.325
- 每 手 1
- 風險率 4.82%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Scholar Rock Holding shares are trading lower following a Q2 EPS miss.
Scholar Rock Holding shares are trading lower following a Q2 EPS miss.
08-06 20:20
Scholar Rock’s Apitegromab Receives FDA Priority Review
Scholar Rock Holding ( ($SRRK) ) just unveiled an update. Scholar Rock announce...
08-06 19:50
Earnings Scheduled For August 6, 2025
Companies Reporting Before The Bell • Lineage (NASDAQ:LINE) is likely to report...
08-06 16:33
Cantor Fitzgerald Initiates Coverage On Scholar Rock Holding with Overweight Rating
Cantor Fitzgerald analyst Eric Schmidt initiates coverage on Scholar Rock Holding (NASDAQ:SRRK) with a Overweight rating.
07-17 20:14
增肌减脂最强者诞生
原标题：增肌减脂最强者诞生 来源：阿基米德Biotech ActRII成为增肌减脂最强通路。 单药减掉的体重100%来自于脂肪，肌肉不掉反而增加2.5%；与司...
06-26 07:42
【爱建医药】回调不改创新药产业趋势，聚焦核心赛道和产业催化
（转自：爱建证券研究所） 投资要点： 医药板块跑输沪深300，创新药大幅回调。本周（6/16~6/22）市场整体震荡向下，沪深300指数-0.45%，银行...
06-25 09:15
Indivior Appoints Tony Kingsley to the Board of Directors
RICHMOND, Va., June 24, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) today announced the appointment of Tony Kingsley to the Board of Directors as an Independent Non-Executive Dire...
06-25 04:12
Bariatric surgery better than GLP-1 drugs for weight loss : ASMBS study
A study presented at the American Society for Metabolic and Bariatric Surgery highlighted that bariatric surgeries, specifically sleeve gastrectomy and gastric bypass, work better in promoting weight ...
06-18 21:51
Market-Moving News for June 18th
SRRK: 23% | Scholar Rock shares are trading higher after a study showed its new drug combination preserves muscle during tirzepatide-induced weight loss. RELI: 70% | Reliance Global shares are trading
06-18 19:29
Scholar Rock Study Shows New Drug Combo Preserves Muscle During Tirzepatide Weight Loss
Scholar Rock (NASDAQ:SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SMA) and additional severe and debilitating
06-18 19:07
